# AEON Biopharma, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/AEON Biopharma, Inc.).

## Overview

AEON Biopharma, Inc. is a clinical-stage biopharmaceutical company developing prabotulinumtoxinA injection (ABP-450) for therapeutic (non-cosmetic) uses as a proposed BOTOX biosimilar in the United States. The company’s strategy is to pursue a Section 351(k) biosimilar Biologics License Application (BLA), using AbbVie’s Botox as the reference product, targeting debilitating medical conditions. ABP-450 is manufactured by Daewoong Pharmaceutical in a cGMP facility that has been approved by the FDA, Health Canada, and the EMA, and the same toxin complex is already approved as a biosimilar in certain international markets. AEON holds exclusive development and distribution rights for certain therapeutic uses across the U.S., Canada, the EU, the UK, and select other territories, positioning it to commercialize if it achieves regulatory approval.

## Products & services

• ABP-450 (prabotulinumtoxinA) therapeutic development program
• Section 351(k) biosimilar BLA development for ABP-450
• Clinical and analytical comparability studies vs. Botox
• Indication screening to expand therapeutic uses of ABP-450
• Future commercialization planning for therapeutic botulinum toxin

- **ABP-450 therapeutic biosimilar development** (85%) — R&D and regulatory work to develop ABP-450 as a therapeutic botulinum toxin biosimilar via a 351(k) BLA.
- **Analytical/clinical comparability and trials** (10%) — Structural analysis and clinical studies (e.g., comparability in cervical dystonia) to support biosimilarity and indications.
- **Commercial readiness and market access preparation** (5%) — Pre-launch planning activities needed to commercialize ABP-450 if approved, including distribution readiness.

- ABP-450 (prabotulinumtoxinA) therapeutic development program
- Section 351(k) biosimilar BLA development for ABP-450
- Clinical and analytical comparability studies vs. Botox
- Indication screening to expand therapeutic uses of ABP-450
- Future commercialization planning for therapeutic botulinum toxin

## Customers

AEON does not currently generate product revenue and is not yet commercializing ABP-450; its end-market customers would be healthcare providers and payors once regulatory approval is obtained. In therapeutic botulinum toxin, demand is driven by neurologists, physiatrists, pain specialists, and other clinicians treating chronic, debilitating conditions where botulinum toxin is an established modality. Payors (commercial insurers and government programs) influence adoption through coverage, step edits, and reimbursement rates, making biosimilar positioning and evidence packages important. If approved, purchasing would typically occur through specialty distributors, group purchasing organizations, and health-system procurement channels, with utilization tied to procedure reimbursement and patient access.

- **Specialist physicians and clinics (therapeutic use)** (primary) — Would use ABP-450 for approved therapeutic indications where botulinum toxin injections are part of care pathways.
- **Hospitals and integrated delivery networks** (secondary) — Would procure product through formulary processes and buy-and-bill workflows for outpatient and specialty clinics.
- **Payors and pharmacy/medical benefit managers** (primary) — Would determine coverage and reimbursement, influencing provider adoption and patient access for biosimilar therapy.
- **Specialty distributors and channel partners** (secondary) — Would handle storage, logistics, and distribution to provider sites for an injectable biologic product.

- Specialist physicians seeking therapeutic botulinum toxin options
- Hospitals and outpatient clinics purchasing for procedures
- Payors evaluating biosimilar value vs. branded Botox
- Specialty distributors supplying injectable biologics to providers
- Patients with debilitating conditions benefiting from access/coverage

## Geography

AEON is U.S.-based and is primarily focused on achieving U.S. market entry for ABP-450 through a 351(k) BLA pathway. The company also holds exclusive development and distribution rights for certain therapeutic uses in Canada, the European Union, the United Kingdom, and certain other international territories, which could expand the addressable commercial footprint over time. Manufacturing for ABP-450 is performed by Daewoong Pharmaceutical in a cGMP facility that has been approved by the FDA, Health Canada, and the EMA, creating operational dependence on an external, non-U.S. manufacturer. Geographic scope matters mainly through regulatory pathways (FDA vs. Health Canada/EMA/UK MHRA), supply chain oversight, and the ability to leverage existing international experience with the same toxin complex.

- Primary near-term focus is U.S. FDA approval and launch planning
- Rights extend to Canada, EU, UK for certain therapeutic uses
- Manufacturing is outsourced to Daewoong (cGMP; FDA/EMA/HC approved)
- International prior approvals (e.g., Mexico, India, Philippines) inform risk
- Cross-border supply chain increases quality and logistics complexity

## Strategy

AEON’s core strategy is to develop ABP-450 as a therapeutic BOTOX biosimilar and pursue U.S. approval via a Section 351(k) BLA, using Botox as the reference product. The company expects to invest heavily in early-stage biosimilar requirements such as primary structural analysis and other analytical work, followed by clinical comparability studies (including potential work in cervical dystonia). In parallel, AEON intends to use a product assessment screening process to identify additional therapeutic indications for future development, expanding the potential label and market opportunity. Execution depends on raising additional capital to fund development through regulatory submission and, if approved, commercialization preparation.

- **Generate biosimilarity package for a 351(k) BLA** (short-term) — Approval requires robust analytical and clinical evidence against the reference product.
- **Expand therapeutic indication set for ABP-450** (medium-term) — More indications can increase addressable market and strengthen commercial rationale.
- **Fundraising to extend operating runway** (short-term) — The company disclosed substantial doubt about going concern without additional financing.

- Advance ABP-450 through 351(k) biosimilar BLA pathway
- Build biosimilarity evidence vs. AbbVie’s Botox reference product
- Run targeted clinical comparability studies (e.g., cervical dystonia)
- Screen and prioritize additional therapeutic indications for ABP-450
- Secure financing to fund R&D and pre-commercial activities

## Risks

AEON is pre-revenue and depends on successful clinical development and regulatory approval of ABP-450; delays or negative outcomes could prevent commercialization entirely. The company disclosed substantial doubt about its ability to continue as a going concern without additional financing, making capital markets access a central business risk. As a biosimilar program, ABP-450 faces scientific and regulatory risk around demonstrating biosimilarity to Botox and translating that into approvable indications, as well as potential competitive responses from the incumbent brand and other toxin products. Operationally, AEON relies on third parties (including Daewoong for manufacturing and CROs/consultants for development), creating supply, quality, and execution risks typical of clinical-stage biotech.

- **Substantial doubt about ability to continue as a going concern** [critical] — Company stated it lacks sufficient cash to fund 12 months of operations without additional financing.
- **No revenue until regulatory approval and commercialization** [high] — Company disclosed it has never generated revenue from ABP-450 and does not expect revenue until approval.
- **Reliance on third-party manufacturer (Daewoong) for ABP-450 supply** [high] — ABP-450 is manufactured externally; any disruption or compliance issue could delay trials or launch.

- Going-concern and financing risk due to limited cash runway
- Regulatory risk: failure/delay in 351(k) BLA approval for ABP-450
- Clinical/analytical comparability risk vs. Botox reference product
- Third-party dependence on Daewoong manufacturing and CRO execution
- Competitive dynamics in therapeutic botulinum toxin market
- Manufacturing quality/compliance risk for biologics supply chain
- IP, exclusivity, and contracting risks tied to licensed rights scope

## Accounting

AEON’s reported results can be heavily influenced by non-cash fair value remeasurements, including contingent consideration, warrants, convertible notes, and other derivative-related items, which can create large period-to-period swings in net income or loss unrelated to operating progress. Cash flow analysis is therefore critical, as operating cash use better reflects the underlying burn rate for a pre-revenue development company. The company’s financing activities (public offerings and convertible notes) and related embedded features increase the importance of understanding classification and valuation of equity-linked instruments. Stock-based compensation is another recurring non-cash expense that affects operating loss and should be considered when assessing run-rate costs versus cash needs.

- **Fair value measurement of contingent consideration** — High volatility in other income/expense and net results
- **Accounting for warrants, convertible notes, and derivative liabilities** — Quarterly comparability and valuation-sensitive P&L items
- **Stock-based compensation** — Higher reported operating expenses vs. cash operating costs

- Fair value changes in contingent consideration can swing earnings
- Warrants and derivative liabilities create non-cash P&L volatility
- Convertible notes fair value/embedded features affect reported results
- Forward purchase/derivative losses may distort operating performance
- Stock-based compensation is a recurring non-cash expense
- Cash burn (operating cash flow) is key for runway assessment

---

*Last updated: 2026-08-11T04:46:17.255580+00:00*